

Didier Samuel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2146212/didier-samuel-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

428
papers

23,799
citations

82
h-index

140
g-index

572
ext. papers

27,387
ext. citations

5.4
avg, IF

6.47
L-index

#	Paper	IF	Citations
428	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.. <i>BMC Infectious Diseases</i> , 2022 , 22, 94	4	0
427	A systematic review of auxiliary liver transplantation of small-for-size grafts in patients with chronic liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100447	10.3	0
426	Impact of COVID - 19 in patients awaiting liver transplantation. <i>Liver International</i> , 2021 ,	7.9	
425	Liver stiffness-based model predicts hepatic venous pressure gradient in patients with liver disease.. <i>Hpb</i> , 2021 ,	3.8	2
424	Mass Spectrometry-Based Proteomics Reveal Alcohol Dehydrogenase 1B as a Blood Biomarker Candidate to Monitor Acetaminophen-Induced Liver Injury. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
423	Prognostic impact of surgical margins for hepatocellular carcinoma according to preoperative alpha-fetoprotein level. <i>Hpb</i> , 2021 ,	3.8	1
422	Management of Hepatitis B Virus Infection Post Transplantation 2021 , 458-468		
421	Management of Hepatitis B Virus Infection Pre Transplantation 2021 , 68-73		
420	Mild increases in plasma creatinine after intermediate to high-risk abdominal surgery are associated with long-term renal injury. <i>BMC Anesthesiology</i> , 2021 , 21, 135	2.4	0
419	Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: The SURFASA score. <i>Journal of Hepatology</i> , 2021 , 74, 1325-1334	13.4	8
418	Hepatic Arteriovenous Malformation: The Search for a PTEN Mutation!. <i>Hepatology</i> , 2021 , 74, 1121-1123 ^{1,2}		
417	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101459	2.4	0
416	Sustained Remission After Treatment Withdrawal in Autoimmune Hepatitis: A Multicenter Retrospective Study. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 2107-2117	4	
415	Predicting the risk of post-hepatectomy portal hypertension using a digital twin: A clinical proof of concept. <i>Journal of Hepatology</i> , 2021 , 74, 661-669	13.4	10
414	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 1097-1108	13.4	41
413	Management of Transplant Patients Infected with HCV 2021 , 153-173		
412	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 583-605	6.1	4

411	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S178-S190	13.4	9
410	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021 , 3, 100298	10.3	3
409	Donor HLA Class 1 Evolutionary Divergence Is a Major Predictor of Liver Allograft Rejection : A Retrospective Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 1385-1394	8	1
408	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021 , 75, 610-622	13.4	25
407	Indocyanine Green Fluorescence Imaging to Predict Graft Survival After Orthotopic Liver Transplantation: A Pilot Study. <i>Liver Transplantation</i> , 2020 , 26, 1263-1274	4.5	4
406	Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020 , 27, 964-973 ^{3,4}		3
405	Phase 3, Multicenter Open-Label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naïve, HCV GT1b-infected patients, with non-severe fibrosis. <i>Liver International</i> , 2020 , 40, 1853-1859	7.9	7
404	Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , 2020 , 73, 130-139	13.4	28
403	Liver transplantation as a rescue therapy for severe neurologic forms of Wilson disease. <i>Neurology</i> , 2020 , 94, e2189-e2202	6.5	16
402	Cyclin-dependent kinase inhibitors p21 and p27 function as critical regulators of liver regeneration following 90% hepatectomy in the rat. <i>World Journal of Hepatology</i> , 2020 , 12, 1198-1210	3.4	2
401	Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2020 , 72, 965-981	11.2	63
400	Comparative analysis of outcomes after liver resection and liver transplantation for early stages hepatocellular carcinoma in HIV-infected patients. An intention-to-treat analysis. <i>Hpb</i> , 2020 , 22, 900-910 ^{3,8}		
399	Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation. <i>Annals of Surgery</i> , 2020 , 272, 820-826	7.8	4
398	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020 , 2, 100170	10.3	23
397	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020 , 73, 842-854	13.4	108
396	Spleen volumetry and liver transient elastography: Predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. <i>Surgery</i> , 2020 , 168, 17-24	3.6	2
395	Management of Fulminant Hepatitis B. <i>Current Infectious Disease Reports</i> , 2019 , 21, 25	3.9	6
394	Impact of the new MELD-based allocation system on waiting list and post-transplant survival - a cohort analysis using the French national CRISTAL database. <i>Transplant International</i> , 2019 , 32, 1061	3	8

393	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019 , 71, 397-408	13.4	163
392	Prognostic Value and Prediction of Extratumoral Microvascular Invasion for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2568-2576	3.1	20
391	Prevention of decompensation in cirrhosis: a new youth for β blockers. <i>Lancet, The</i> , 2019 , 393, 1571-1572	40	1
390	Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference. <i>Journal of Hepatology</i> , 2019 , 70, 1297-1300	13.4	2
389	Approaches for patients with very high MELD scores. <i>JHEP Reports</i> , 2019 , 1, 53-65	10.3	4
388	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019 , 19, 300	4	2
387	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019 , 393, 1453-1464	40	287
386	Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. <i>Liver International</i> , 2019 , 39, 136-146	7.9	6
385	Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. <i>European Journal of Clinical Pharmacology</i> , 2019 , 75, 1555-1563	2.8	
384	A Critical Review of MELD as a Reliable Tool for Transplant Prioritization. <i>Seminars in Liver Disease</i> , 2019 , 39, 403-413	7.3	18
383	Management of HCV Infection After Liver Transplantation 2019 , 753-764		
382	HCV-positive organ transplants in HCV-negative recipients. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 745-747	18.8	0
381	Evaluation of a micro-spectrometer for the real-time assessment of liver graft with mild-to-moderate macrosteatosis: A proof of concept study. <i>Journal of Hepatology</i> , 2019 , 70, 423-430	13.4	9
380	Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?". <i>Journal of Hepatology</i> , 2019 , 70, 566-567	13.4	1
379	Liver transplantation in patients with liver failure related to exertional heatstroke. <i>Journal of Hepatology</i> , 2019 , 70, 431-439	13.4	10
378	Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1682-1689	6.1	7
377	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018 , 68, 1181-1190	13.4	222
376	The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. <i>Liver International</i> , 2018 , 38 Suppl 1, 139-145	7.9	78

375	Long-lasting successful dissemination of resistance to oxazolidinones in MDR Staphylococcus epidermidis clinical isolates in a tertiary care hospital in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 41-51	5.1	21
374	Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1013-1018	11.6	37
373	Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study. <i>Transplantation</i> , 2018 , 102, 119-126	1.8	15
372	Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. <i>BMC Medicine</i> , 2018 , 16, 113	11.4	30
371	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?". <i>Journal of Hepatology</i> , 2018 , 69, 550-551	13.4	0
370	Reply to: "Mortality due to immunotherapy related hepatitis". <i>Journal of Hepatology</i> , 2018 , 69, 978-979	13.4	
369	Enteric Delivery of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and Controls Inflammation in Mice With Colitis. <i>Gastroenterology</i> , 2018 , 154, 1009-1023.e14	13.3	60
368	Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant. <i>Hepatology</i> , 2018 , 67, 86-96	11.2	33
367	Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018 , 25, 253-260	2.7	5
366	Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". <i>Journal of Hepatology</i> , 2018 , 69, 1397-1398	13.4	1
365	Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. <i>Journal of Hepatology</i> , 2018 , 69, 810-817	13.4	137
364	EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. <i>Journal of Hepatology</i> , 2017 , 66, 1047-1081	13.4	368
363	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. <i>Transplantation</i> , 2017 , 101, S1-S56	1.8	141
362	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017 , 101, 945-955	1.8	63
361	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017 , 101, 956-967	1.8	40
360	HCV and HEV recurrence after liver transplantation: one antiviral therapy for two viruses. <i>Transplant International</i> , 2017 , 30, 318-319	3	7
359	Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms: Outcomes and Prognostic Factors. <i>Transplantation</i> , 2017 , 101, 1830-1837	1.8	20
358	SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 66, S85-S86	13.4	23

357	Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. <i>Journal of Hepatology</i> , 2017 , 67, 708-715	13.4	165
356	Treatment and prognosis of acute severe autoimmune hepatitis. <i>Journal of Hepatology</i> , 2017 , 66, S4	13.4	7
355	Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. <i>Liver International</i> , 2017 , 37, 1869-1876	7.9	13
354	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017 , 67, 585-602	13.4	57
353	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017 , 65, 1683-1692	11.2	40
352	A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation. <i>Liver Transplantation</i> , 2017 , 23, 143-154	4.5	97
351	Prospective validation of transient elastography for staging liver fibrosis in patients undergoing hepatectomy and liver transplantation. <i>Journal of Hepatology</i> , 2017 ,	13.4	5
350	Immunotherapy in liver transplantation. <i>Journal of Hepatology</i> , 2017 , 67, 874-875	13.4	3
349	Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. <i>American Journal of Transplantation</i> , 2017 , 17, 2869-2878	8.7	6
348	Cutting out the roots of acute hepatitis C. <i>Lancet Infectious Diseases, The</i> , 2017 , 17, 125-127	25.5	
347	Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017 , 41, 56-65	2.4	
346	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017 , 66, 39-47	13.4	80
345	Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. <i>Hepatology</i> , 2016 , 64, 1049-56	11.2	91
344	Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 1432-1441	8.4	26
343	Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study. <i>Transplantation</i> , 2016 , 100, 1507-12	1.8	16
342	Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. <i>Liver Transplantation</i> , 2016 , 22, 1367-78	4.5	25
341	SOF/VEL for 12 Weeks Results in High SVR12 Rates in Subjects with Negative Predictors of Response to Treatment: An Integrated Analysis of Efficacy from the Astral-1, Astral-2 and Astral-3 Studies. <i>Journal of Hepatology</i> , 2016 , 64, S787-S788	13.4	4
340	Dynamic outcome prediction for paracetamol-related acute liver failure. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 177-178	18.8	

339	Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients. <i>Transplantation</i> , 2016 , 100, 2129-2137	1.8	18
338	Multimodality Imaging of Cardiac Transthyretin Amyloidosis 16 Years After a Domino Liver Transplantation. <i>American Journal of Transplantation</i> , 2016 , 16, 2208-2212	8.7	8
337	Autoantibody signatures defined by serological proteome analysis in sera from patients with cholangiocarcinoma. <i>Journal of Translational Medicine</i> , 2016 , 14, 17	8.5	13
336	New perspectives for preventing hepatitis C virus liver graft infection. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, 735-745	25.5	31
335	Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. <i>Journal of Hepatology</i> , 2016 , 65, 711-718	13.4	63
334	Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature. <i>Journal of Translational Medicine</i> , 2016 , 14, 9	8.5	10
333	Pros and Cons: Usage of organs from donors infected with hepatitis C virus - Revision in the direct-acting antiviral era. <i>Journal of Hepatology</i> , 2016 , 64, 226-31	13.4	46
332	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, 685-697	25.5	346
331	Quality of life 10 years after liver transplantation: The impact of graft histology. <i>World Journal of Transplantation</i> , 2016 , 6, 703-711	2.3	7
330	Hepatitis B Recurrence: Major Milestones and Current Status 2016 , 13-34		
329	Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. <i>World Journal of Gastroenterology</i> , 2016 , 22, 4547-58	5.6	11
328	A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases. <i>PLoS ONE</i> , 2016 , 11, e0150733	3.7	5
327	Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. <i>Chest</i> , 2016 , 150, 256-8	5.3	11
326	Intention-to-treat analysis of percutaneous endovascular treatment of hepatic artery stenosis after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2016 , 22, 923-33	4.5	30
325	Repeat liver retransplantation: rationale and outcomes. <i>Clinical Transplantation</i> , 2016 , 30, 312-9	3.8	15
324	Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. <i>Transplantation</i> , 2016 , 100, 1705-13	1.8	11
323	Liver Transplantation in Severe Neurological Forms of Wilson Disease; The French Experience. <i>Journal of Hepatology</i> , 2016 , 64, S153	13.4	2
322	Neuroinflammation in liver disease: sessional talks from ISHEN. <i>Metabolic Brain Disease</i> , 2016 , 31, 1339-1354	13.4	8

321	Optimum timing of treatment for hepatitis C infection relative to liver transplantation. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 165-172	18.8	17
320	Single-Nucleotide Resolution Mapping of Hepatitis B Virus Promoters in Infected Human Livers and Hepatocellular Carcinoma. <i>Journal of Virology</i> , 2016 , 90, 10811-10822	6.6	14
319	Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 957-966	6.1	28
318	News and challenges in the treatment of hepatitis C in liver transplantation. <i>Liver International</i> , 2016 , 36 Suppl 1, 34-42	7.9	15
317	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. <i>Journal of Hepatology</i> , 2015 , 62, 1047-55	13.4	64
316	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015 , 62, 831-40	13.4	207
315	The implementation of an Intensive Care Information System allows shortening the ICU length of stay. <i>Journal of Clinical Monitoring and Computing</i> , 2015 , 29, 263-9	2	7
314	Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2015 , 17, 322-7	2.7	19
313	G02 : Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: Preliminary results of the prospective solar 2 trial. <i>Journal of Hepatology</i> , 2015 , 62, S187-S188	13.4	53
312	O056 : Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. <i>Journal of Hepatology</i> , 2015 , 62, S219-S220	13.4	27
311	O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB). <i>Journal of Hepatology</i> , 2015 , 62, S251-S252	13.4	10
310	LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*. <i>Journal of Hepatology</i> , 2015 , 62, S258-S259	13.4	23
309	LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather. <i>Journal of Hepatology</i> , 2015 , 62, S278	13.4	15
308	P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2015 , 62, S541-S542	13.4	2
307	P0774 : Ledipasvir/sofosbuvir with ribavirin is safe in >600 decompensated and post liver transplantation patients with HCV infection: An integrated safety analysis of the solar 1 and solar 2 trials. <i>Journal of Hepatology</i> , 2015 , 62, S620-S621	13.4	13
306	P0779 : Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. <i>Journal of Hepatology</i> , 2015 , 62, S623	13.4	6
305	P0837 : Efficacy of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis. <i>Journal of Hepatology</i> , 2015 , 62, S651	13.4	2
304	Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?. <i>Journal of Hepatology</i> , 2015 , 63, 83-92	13.4	69

303	Prevention of Post-transplant HBV. <i>Current Hepatology Reports</i> , 2015 , 14, 153-163	1	
302	Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , 2015 , 15, 1267-82	8.7	50
301	The role of corticosteroids in acute-severe autoimmune hepatitis is still highly debatable. <i>Journal of Hepatology</i> , 2015 , 63, 1041-2	13.4	9
300	Patients with acute liver failure listed for superurgent liver transplantation in France: reevaluation of the Clichy-Villejuif criteria. <i>Liver Transplantation</i> , 2015 , 21, 512-23	4.5	35
299	Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2015 , 34, 604-12	5.8	6
298	From immunosuppression to tolerance. <i>Journal of Hepatology</i> , 2015 , 62, S170-85	13.4	101
297	Transplantation for Hepatitis A and B 2015 , 105-119		
296	Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. <i>Aids</i> , 2015 , 29, 53-8	3.5	24
295	Management of post transplant hepatitis C in the direct antiviral agents era. <i>Hepatology International</i> , 2015 , 9, 192-201	8.8	7
294	Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus. <i>Radiology</i> , 2015 , 277, 443-53	20.5	13
293	Liver transplantation: The effect of new HCV drugs on liver transplantation outcomes. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015 , 12, 559-60	24.2	1
292	P0804 : Efficacy of sofosbuvir-based treatment regimens in HIV/HCV co-infected patients after liver transplantation: The ANRS CO23 CUPILT study. <i>Journal of Hepatology</i> , 2015 , 62, S635-S636	13.4	2
291	Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. <i>Gastroenterology</i> , 2015 , 149, 1378-1380.e1	13.3	60
290	Alcoholic liver disease: Clinical and translational research. <i>Experimental and Molecular Pathology</i> , 2015 , 99, 596-610	4.4	28
289	Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. <i>Gastroenterology</i> , 2015 , 148, 108-17	13.3	280
288	Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals. <i>Liver International</i> , 2015 , 35 Suppl 1, 44-50	7.9	20
287	Hepatitis E infection in patients with severe acute alcoholic hepatitis. <i>Liver International</i> , 2015 , 35, 870-57.9		20
286	Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. <i>Transplantation</i> , 2015 , 99, 1321-34	1.8	45

285	Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). <i>Antiviral Therapy</i> , 2015 , 21, 195-205	1.6	15
284	Changing outcomes in acute liver failure: Can we transplant only the ones who really need it?. <i>Liver Transplantation</i> , 2015 , 21 Suppl 1, S36-8	4.5	5
283	Infectious complications after liver transplantation in human immunodeficiency virus-infected recipients. <i>Transplant Infectious Disease</i> , 2015 , 17, 662-70	2.7	5
282	Liver metastases from meningeal hemangiopericytoma. <i>Liver International</i> , 2015 , 35, 2337	7.9	3
281	Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation. <i>Hepatology</i> , 2015 , 62, 179-87	11.2	25
280	Personalized adapted physical activity before liver transplantation: acceptability and results. <i>Transplantation</i> , 2015 , 99, 145-50	1.8	68
279	Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?. <i>Transplantation</i> , 2015 , 99, 1847-54	1.8	201
278	Spontaneous Splenorenal Shunt in Liver Transplantation: Results of Left Renal Vein Ligation Versus Renoportal Anastomosis. <i>Transplantation</i> , 2015 , 99, 2576-85	1.8	26
277	Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. <i>Viruses</i> , 2015 , 7, 5155-68	6.2	19
276	The Reg3 β (HIP/PAP) Lectin Suppresses Extracellular Oxidative Stress in a Murine Model of Acute Liver Failure. <i>PLoS ONE</i> , 2015 , 10, e0125584	3.7	11
275	Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?. <i>PLoS ONE</i> , 2015 , 10, e0138091	3.7	32
274	Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. <i>Liver International</i> , 2015 , 35, 1872-6	7.9	15
273	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015 , 39, 443-50	2.4	4
272	Quantitative assessment of liver steatosis on tissue section using infrared spectroscopy. <i>Gastroenterology</i> , 2015 , 148, 295-7	13.3	14
271	Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. <i>Gastroenterology</i> , 2014 , 147, 132-142.e4	13.3	207
270	Outcome of patients with cirrhosis requiring mechanical ventilation in ICU. <i>Journal of Hepatology</i> , 2014 , 60, 570-8	13.4	89
269	Long term results of liver transplantation for Wilson's disease: experience in France. <i>Journal of Hepatology</i> , 2014 , 60, 579-89	13.4	78
268	Prevention of hepatitis B virus reinfection in liver transplant recipients. <i>Intervirology</i> , 2014 , 57, 196-201	2.5	20

267	Expansion of CMV-mediated NKG2C+ NK cells associates with the development of specific de novo malignancies in liver-transplanted patients. <i>Journal of Immunology</i> , 2014 , 192, 503-11	5.3	19
266	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014 , 61, 1038-47	13.4	512
265	Liver transplantation for alcoholic hepatitis. Current situation and future. <i>Hepatology International</i> , 2014 , 8 Suppl 2, 481-5	8.8	2
264	Management of HCV transplant patients with triple therapy. <i>Liver International</i> , 2014 , 34 Suppl 1, 46-52	7.9	21
263	Should we screen blood products for hepatitis E virus RNA?. <i>Lancet, The</i> , 2014 , 383, 218	4.0	38
262	Severe fibrosis in patients with recurrent hepatitis C after liver transplantation: a French experience on 250 patients over 15 years (the Orfèvre study). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014 , 38, 292-9	2.4	4
261	P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY. <i>Journal of Hepatology</i> , 2014 , 60, S499	13.4	20
260	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. <i>Hepatology International</i> , 2014 , 8, 453-71	8.8	427
259	Long-term results of combined liver-kidney transplantation for primary hyperoxaluria type 1: the French experience. <i>Liver Transplantation</i> , 2014 , 20, 1475-85	4.5	22
258	Optimal Management of HCV Transplant Patients. <i>Current Hepatology Reports</i> , 2014 , 13, 304-313	1	
257	Transplantation-induced cancers: Emerging evidence that clonal CMV-specific NK cells are causal immunogenic factors. <i>Onc Immunology</i> , 2014 , 3, e28782	7.2	2
256	Do the epidemiology, physiological mechanisms and characteristics of hepatocellular carcinoma in HIV-infected patients justify specific screening policies?. <i>Aids</i> , 2014 , 28, 1379-91	3.5	21
255	Telbivudine improves renal function in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2014 , 146, 138-146.e5	13.3	90
254	Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. <i>Journal of Hepatology</i> , 2014 , 60, 78-86	13.4	163
253	Journal of Hepatology, an international top rank journal. <i>Journal of Hepatology</i> , 2014 , 60, 3	13.4	7
252	P1319 ONCE-DAILY SIMEPREVR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL. <i>Journal of Hepatology</i> , 2014 , 60, S535	13.4	17
251	Hepatitis C and Liver Transplantation in the HIV Co-infected Patients 2014 , 65-76		
250	The international vision of the Journal of Hepatology. <i>Journal of Hepatology</i> , 2013 , 58, 3	13.4	3

249	The positive financial impact of using an Intensive Care Information System in a tertiary Intensive Care Unit. <i>International Journal of Medical Informatics</i> , 2013 , 82, 177-84	5.3	6
248	60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC). <i>Journal of Hepatology</i> , 2013 , 58, S27	13.4	23
247	Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. <i>Annals of Internal Medicine</i> , 2013 , 159, 522-31	8	170
246	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. <i>Journal of Hepatology</i> , 2013 , 59, 434-41	13.4	367
245	Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach. <i>Liver Transplantation</i> , 2013 , 19, 69-77	4.5	17
244	HCV core-mediated activation of latent TGF- β via thrombospondin drives the crosstalk between hepatocytes and stromal environment. <i>Journal of Hepatology</i> , 2013 , 59, 1160-8	13.4	48
243	Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. <i>Clinics in Liver Disease</i> , 2013 , 17, 451-73	4.6	13
242	991 ACUTE LIVER FAILURE IN HIV INFECTED PATIENTS: A SINGLE CENTER EXPERIENCE. <i>Journal of Hepatology</i> , 2013 , 58, S409	13.4	4
241	140 IMPACT OF SARCOPENIA ON MORTALITY AFTER LIVER TRANSPLANTATION IN HIV INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2013 , 58, S63	13.4	3
240	1422 END OF TREATMENT RESPONSE AFTER PROTEASE INHIBITOR (PI)- BASED THERAPY FOR HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A MULTICENTRIC EUROPEAN EXPERIENCE. <i>Journal of Hepatology</i> , 2013 , 58, S572-S573	13.4	9
239	Human herpesvirus 8 (HHV8) transmission and related morbidity in organ recipients. <i>American Journal of Transplantation</i> , 2013 , 13, 207-13	8.7	48
238	Current management and perspectives for HCV recurrence after liver transplantation. <i>Liver International</i> , 2013 , 33 Suppl 1, 56-62	7.9	43
237	Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders. <i>Pathobiology</i> , 2013 , 80, 53-9	3.6	16
236	HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. <i>Cell Host and Microbe</i> , 2013 , 13, 302-13	23.4	123
235	Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma. <i>Hepatology International</i> , 2013 , 7, 788-91	8.8	3
234	Liver transplantation in the human immunodeficiency virus-hepatitis C virus coinfecting patient: time to sum up. <i>Hepatology</i> , 2013 , 57, 409-11	11.2	3
233	Immunoproteomic analysis of potentially severe non-graft-versus-host disease hepatitis after allogeneic bone marrow transplantation. <i>Hepatology</i> , 2013 , 57, 689-99	11.2	8
232	Cirrhosis patients in the ICU: prognostic markers and outcome. <i>Current Opinion in Critical Care</i> , 2013 , 19, 154-60	3.5	51

231	Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation. <i>American Journal of Transplantation</i> , 2013 , 13, 2458-61	8.7	32
230	Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. <i>Clinical Transplantation</i> , 2013 , 27, E454-61	3.8	66
229	Reversibility of acquired amyloid polyneuropathy after liver retransplantation. <i>American Journal of Transplantation</i> , 2013 , 13, 2734-8	8.7	19
228	Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients. <i>American Journal of Clinical Pathology</i> , 2013 , 140, 403-9	1.9	23
227	Histologic findings predictive of a diagnosis of de novo autoimmune hepatitis after liver transplantation in adults. <i>Transplantation</i> , 2013 , 96, 670-8	1.8	29
226	Posttransplantation hepatitis E: transfusion-transmitted hepatitis rising from the ashes. <i>Transplantation</i> , 2013 , 96, e4-6	1.8	33
225	Postliver transplantation pulmonary complications: is modified clinical pulmonary infection score applicable?. <i>Transplantation</i> , 2013 , 95, e43-4	1.8	
224	Lengthy follow-up after liver transplantation for nodular regenerative hyperplasia in human immunodeficiency virus-infected patients: does the disease recur?. <i>Transplantation</i> , 2013 , 96, e79-81	1.8	1
223	8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC). <i>Journal of Hepatology</i> , 2012 , 56, S4	13.4	47
222	47 EFFICACY AND SAFETY OF PROTEASE INHIBITORS FOR SEVERE HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A FIRST MULTICENTRIC EXPERIENCE. <i>Journal of Hepatology</i> , 2012 , 56, S21	13.4	19
221	Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha. <i>Transplant International</i> , 2012 , 25, 941-7	3	9
220	Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG. <i>Cancer Research</i> , 2012 , 72, 5505-15	10.1	29
219	Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5728-34	5.9	45
218	Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. <i>Journal of Hepatology</i> , 2012 , 56, 95-102	13.4	133
217	Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. <i>Journal of Hepatology</i> , 2012 , 56, 840-7	13.4	34
216	Reply to: Patients with cirrhosis admitted to an Intensive Care Unit. <i>Journal of Hepatology</i> , 2012 , 57, 231-232	13.4	2
215	Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFN α plus ribavirin. <i>Journal of Hepatology</i> , 2012 , 57, 564-71	13.4	24
214	Combined prophylaxis might still be better than monoprophylaxis with entecavir following liver transplantation for hepatitis B. <i>Gastroenterology</i> , 2012 , 142, e34; author reply e34-5	13.3	4

213	A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients. <i>Journal of Transplantation</i> , 2012 , 2012, 894215	2.3	27
212	Hepatitis C virus treatment pre- and post-liver transplantation. <i>Liver International</i> , 2012 , 32 Suppl 1, 120-89	7.8	54
211	Liver transplantation in delta virus infection. <i>Seminars in Liver Disease</i> , 2012 , 32, 245-55	7.3	35
210	Recombination of hepatitis B virus DNA in patients with HIV. <i>Gut</i> , 2012 , 61, 1197-208	19.2	6
209	Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases. <i>Gut</i> , 2012 , 61, 1098-100	19.2	3
208	Pulmonary complications after elective liver transplantation-incidence, risk factors, and outcome. <i>Transplantation</i> , 2012 , 94, 532-8	1.8	64
207	Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy?. <i>Annals of Surgery</i> , 2012 , 256, 883-91	7.8	63
206	Epidemiology of liver failure. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011 , 35, 610-7	2.4	40
205	Early liver transplantation for severe alcoholic hepatitis. <i>New England Journal of Medicine</i> , 2011 , 365, 1790-800	59.2	558
204	Low-dose peginterferon alfa-2a is safe and produces a sustained virologic response in patients with chronic hepatitis C and end-stage renal disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 242-8	6.9	24
203	Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. <i>Journal of Hepatology</i> , 2011 , 54, 481-8	13.4	63
202	Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with a synthetic cohort. <i>Aids</i> , 2011 , 25, 1675-6	3.5	7
201	Non-invasive ICG-clearance: a useful tool for the management of hepatic artery thrombosis following liver transplantation. <i>Clinical Transplantation</i> , 2011 , 25, 297-301	3.8	23
200	The difficulties of managing severe hepatitis B virus reactivation. <i>Liver International</i> , 2011 , 31 Suppl 1, 104-10	7.9	46
199	Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. <i>Liver International</i> , 2011 , 31, 676-84	7.9	39
198	Short- and long-term donor morbidity in right lobe living donor liver transplantation: 91 consecutive cases in a European Center. <i>American Journal of Transplantation</i> , 2011 , 11, 101-10	8.7	71
197	Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. <i>American Journal of Transplantation</i> , 2011 , 11, 1686-95	8.7	45
196	Respiratory impact of paracentesis in cirrhotic patients with acute lung injury. <i>Journal of Critical Care</i> , 2011 , 26, 257-61	4	16

195	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. <i>Liver Transplantation</i> , 2011 , 17, 167-77	4.5	47
194	Significance of isolated hepatic veno-occlusive disease/sinusoidal obstruction syndrome after liver transplantation. <i>Liver Transplantation</i> , 2011 , 17, 798-808	4.5	31
193	Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system. <i>Liver Transplantation</i> , 2011 , 17, 1137-51	4.5	54
192	Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. <i>Liver Transplantation</i> , 2011 , 17 Suppl 2, S6-13	4.5	47
191	Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. <i>Hepatology</i> , 2011 , 53, 475-82	11.2	33
190	Human hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers. <i>Hepatology</i> , 2011 , 53, 618-27	11.2	30
189	Reply:. <i>Hepatology</i> , 2011 , 53, 2138-2139	11.2	
188	Autoimmune acute liver failure. <i>Hepatology</i> , 2011 , 54, 372-3; author reply 373	11.2	7
187	Successful long-term outcome of ABO-incompatible liver transplantation using antigen-specific immunoadsorption columns. <i>Therapeutic Apheresis and Dialysis</i> , 2010 , 14, 116-23	1.9	16
186	Factors associated with nutritional status in liver transplant patients who survived the first year after transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 391-6	4	17
185	ATP release after partial hepatectomy regulates liver regeneration in the rat. <i>Journal of Hepatology</i> , 2010 , 52, 54-62	13.4	77
184	Prognosis indicator in acute liver failure: Is there a place for cell death markers?. <i>Journal of Hepatology</i> , 2010 , 53, 593-5	13.4	12
183	29 EARLY TRANSPLANTATION IMPROVES SURVIVAL OF NON-RESPONDERS TO CORTICOSTEROIDS IN SEVERE ALCOHOLIC HEPATITIS: A CHALLENGE TO THE 6 MONTH RULE OF ABSTINENCE. <i>Journal of Hepatology</i> , 2010 , 52, S13	13.4	5
182	30 ACUTE LIVER FAILURE: CURRENT EUROPEAN PERSPECTIVE. <i>Journal of Hepatology</i> , 2010 , 52, S13-S14	13.4	4
181	Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. <i>Transplantation</i> , 2010 , 89, 1504-10	1.8	39
180	EFFICACY AND LONG-TERM OUTCOME OF AMPHOTERICIN B LIPID COMPLEX (ABLC) PROPHYLAXIS IN HIGH RISK LIVER TRANSPLANT RECIPIENTS IN THE CURRENT PRACTICE. <i>Transplantation</i> , 2010 , 90, 116	1.8	
179	Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. <i>American Journal of Transplantation</i> , 2010 , 10, 129-37	8.7	182
178	Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. <i>Liver Transplantation</i> , 2010 , 16, 885-94	4.5	23

177	Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. <i>Liver Transplantation</i> , 2010 , 16, 1136-46	4.5	24
176	Hepatitis C virus: Up to the minute. <i>Liver Transplantation</i> , 2010 , 16, S26-S35	4.5	7
175	Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. <i>PLoS ONE</i> , 2009 , 4, e4355	3.7	91
174	Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfecting patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. <i>Aids</i> , 2009 , 23, 1069-76	3.5	39
173	Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. <i>American Journal of Transplantation</i> , 2009 , 9, 327-36	8.7	210
172	Plasma disappearance rate of indocyanine green: a tool to evaluate early graft outcome after liver transplantation. <i>Liver Transplantation</i> , 2009 , 15, 1358-64	4.5	60
171	Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation. <i>Liver Transplantation</i> , 2009 , 15, 1336-42	4.5	5
170	Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). <i>Hepatology International</i> , 2009 , 3, 269-82	8.8	615
169	MELD-Na as a prognostic score for cirrhotic patients: Hyponatremia and ascites are back in the game. <i>Journal of Hepatology</i> , 2009 , 50, 836-8	13.4	31
168	Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfecting patients (ANRS-HC08 "THEVIC" trial). <i>Journal of Hepatology</i> , 2009 , 51, 1000-9	13.4	11
167	Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. <i>Digestive and Liver Disease</i> , 2009 , 41, 350-6	3.3	60
166	220 PREDICTIVE FACTORS OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH FULMINANT AND SUBFULMINANT HEPATIC FAILURE: RESULTS FROM A RANDOMIZED CONTROLLED MULTICENTER TRIAL. <i>Journal of Hepatology</i> , 2009 , 50, S89-S90	13.4	15
165	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 719-27	4.3	35
164	Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. <i>Gastroenterology</i> , 2008 , 134, 1890-9; quiz 2155	13.3	131
163	Are HIV-infected patients candidates for liver transplantation?. <i>Journal of Hepatology</i> , 2008 , 48, 697-707	13.4	37
162	Molecular tools and hepatocellular carcinoma: Adding help or confusion in liver transplantation?. <i>Journal of Hepatology</i> , 2008 , 49, 498-501	13.4	0
161	Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. <i>Human Gene Therapy</i> , 2008 , 19, 915-26	4.8	26
160	Pneumocystis pneumonia: an opportunistic infection occurring in patients with severe alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008 , 20, 26-8	2.2	11

159	Survival and recurrence of hepatitis C after liver transplantation in patients coinfecting with human immunodeficiency virus and hepatitis C virus. <i>Hepatology</i> , 2008 , 47, 407-17	11.2	158
158	A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. <i>Liver Transplantation</i> , 2008 , 14, 1194-8	4.5	42
157	Chickenpox-associated fulminant hepatitis that led to liver transplantation in a 63-year-old woman. <i>Liver Transplantation</i> , 2008 , 14, 1309-12	4.5	20
156	Etiology and prognosis of fulminant hepatitis in adults. <i>Liver Transplantation</i> , 2008 , 14 Suppl 2, S67-79	4.5	131
155	Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. <i>Liver Transplantation</i> , 2008 , 14, 1766-77	4.5	116
154	Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. <i>Hepatology</i> , 2008 , 47, 937-48	11.2	30
153	Liver transplantation in viral hepatitis: prevention of recurrence. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2008 , 22, 1153-69	2.5	12
152	Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 941-52	6.2	48
151	Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma. <i>Gastroenterology</i> , 2007 , 132, 1495-503	13.3	20
150	Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection. <i>Hepatology</i> , 2007 , 46, 1704-12	11.2	39
149	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. <i>Liver Transplantation</i> , 2007 , 13, 349-60	4.5	204
148	Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. <i>Liver Transplantation</i> , 2007 , 13, 996-1003	4.5	189
147	Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. <i>Liver Transplantation</i> , 2007 , 13, 1004-10	4.5	32
146	Domino liver transplantation from familial amyloidotic polyneuropathy donors: how close is the damocles sword to the recipient?. <i>Transplant International</i> , 2007 , 20, 921-3	3	8
145	Risk factors for hepatitis C recurrence after liver transplantation. <i>Journal of Viral Hepatitis</i> , 2007 , 14 Suppl 1, 89-96	3.4	69
144	Identification by proteomic tool of atypical anti-liver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1109, 345-57	6.5	26
143	A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2007 , 11, 1328-32	3.3	21
142	New aspect of immunosuppressive treatment in liver transplantation. How could you induce tolerance in liver transplantation?. <i>Transplant Immunology</i> , 2007 , 17, 98-107	1.7	11

141	Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: difficult to manage but essential for success. <i>Journal of Hepatology</i> , 2007 , 46, 988-91	13.4	14
140	[139] POST-ASPIRIN REYE'S SYNDROME IN YOUNG ADULTS: FREQUENT AGGRAVATION OF ENCEPHALOPATHY BY NEUROTROPIC DRUGS AND SPONTANEOUS RECOVERY. <i>Journal of Hepatology</i> , 2007 , 46, S63	13.4	3
139	Medical community preferences concerning adult living related donor liver transplantation. <i>Gastroenterologie Clinique Et Biologique</i> , 2006 , 30, 183-7		2
138	Prise en charge de la résistance à la lamivudine en transplantation hépatique pour hépatopathie B. <i>Gastroenterologie Clinique Et Biologique</i> , 2006 , 30, 26-30		
137	Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. <i>Liver Transplantation</i> , 2006 , 12, 1640-8	4.5	105
136	12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. <i>Liver Transplantation</i> , 2006 , 12, 1464-72	4.5	83
135	Liver transplantation for fulminant hepatitis related to nevirapine therapy. <i>Liver Transplantation</i> , 2006 , 12, 1880-2	4.5	18
134	Clinical and therapeutic implications of hepatitis C virus compartmentalization. <i>Gastroenterology</i> , 2006 , 131, 76-84	13.3	76
133	Cadaveric full-size liver transplantation and the graft alternatives in adults: a comparative study from a single centre. <i>Journal of Hepatology</i> , 2006 , 44, 118-25	13.4	19
132	Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. <i>Journal of Hepatology</i> , 2006 , 45, 355-60	13.4	75
131	Hépatites auto-immunes: aspects physiopathologiques, cliniques, histologiques et thérapeutiques. <i>EMC - Hépatologie</i> , 2006 , 1, 1-8		
130	Liver retransplantation: a model for determining long-term survival. <i>Transplantation</i> , 2006 , 81, 1016-21	1.8	38
129	Aspects of hepatitis C virus infection relating to liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 313-20	2.2	11
128	Liver transplantation in HIV-infected patients. <i>Current Opinion in Organ Transplantation</i> , 2006 , 11, 608-612	5	1
127	Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2006 , 12, 4911-3	5.6	10
126	Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , 2005 , 42, 341-9	13.4	40
125	The questionable role of immunization against hepatitis B in HBV infected liver transplant patients. <i>Journal of Hepatology</i> , 2005 , 43, 203-6	13.4	6
124	Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. <i>Transplant International</i> , 2005 , 17, 759-66	3	9

123	Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. <i>Transplant International</i> , 2005 , 17, 746-58	3	5
122	Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis?. <i>Clinical Transplantation</i> , 2005 , 19, 591-9	3.8	20
121	Male cell microchimerism in normal and diseased female livers from fetal life to adulthood. <i>Hepatology</i> , 2005 , 42, 35-43	11.2	53
120	Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. <i>Liver Transplantation</i> , 2005 , 11, 716-732	4.5	134
119	Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. <i>Liver Transplantation</i> , 2005 , 11, 1550-5	4.5	89
118	Compartmentalization of hepatitis C virus genotypes between plasma and peripheral blood mononuclear cells. <i>Journal of Virology</i> , 2005 , 79, 6349-57	6.6	123
117	Transplantation for Viral Hepatitis A and B 2005 , 115-128		
116	Management of hepatitis B in liver transplantation patients. <i>Seminars in Liver Disease</i> , 2004 , 24 Suppl 1, 55-62	7.3	46
115	Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 1779-85	4.3	27
114	Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. <i>Transplant International</i> , 2004 , 17, 746-758	3	13
113	Transplantation and prevention of reinfection. <i>Current Hepatitis Reports</i> , 2004 , 3, 67-75		1
112	No hepatic iron overload 12 years after liver transplantation for hereditary hemochromatosis. <i>Hepatology</i> , 2004 , 40, 762; author reply 762	11.2	11
111	Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. <i>Liver Transplantation</i> , 2004 , 10, 295-300	4.5	54
110	Evolving strategies to prevent HBV recurrence. <i>Liver Transplantation</i> , 2004 , 10, S74-85	4.5	76
109	Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. <i>Liver Transplantation</i> , 2004 , 10, 1454-60	4.5	46
108	Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2004 , 41, 446-53	13.4	48
107	Treatment of patients with hepatic failure: the difficult place of liver support systems. <i>Journal of Hepatology</i> , 2004 , 41, 694-5	13.4	12
106	Place of the liver biopsy in liver transplantation. <i>Journal of Hepatology</i> , 2004 , 41, 897-901	13.4	6

105	Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. <i>Transplantation</i> , 2004 , 77, 1632-8	1.8	105
104	Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?. <i>Annals of Surgery</i> , 2003 , 238, 508-18; discussion 518-9	7.8	254
103	Bioartificial liver: present and future. <i>Transplantation</i> , 2003 , 75, 1769-70	1.8	1
102	Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. <i>Transplantation</i> , 2003 , 76, 1699-704	1.8	123
101	Adoptive transfer of immunity to HBV through liver graft: does it prevent HBV recurrence?. <i>Hepatology</i> , 2003 , 37, 16-8	11.2	2
100	All liver recipients benefit from the protocol 10-year liver biopsies. <i>Hepatology</i> , 2003 , 37, 1293-301	11.2	94
99	HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. <i>Hepatology</i> , 2003 , 38, 86-95	11.2	180
98	Fulminant hepatitis after grand mal seizures: mechanisms and role of liver transplantation. <i>Hepatology</i> , 2003 , 38, 443-51	11.2	10
97	Viral and clinical factors associated with the fulminant course of hepatitis A infection. <i>Hepatology</i> , 2003 , 38, 613-8	11.2	141
96	Longitudinal prospective evaluation of quality of life in adult patients before and one year after liver transplantation. <i>Liver Transplantation</i> , 2003 , 9, 703-11	4.5	72
95	Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. <i>American Journal of Transplantation</i> , 2003 , 3, 348-56	8.7	92
94	Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. <i>Hepatology</i> , 2003 , 38, 1419-27	11.2	85
93	Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. <i>Journal of Viral Hepatitis</i> , 2003 , 10, 197-204	3.4	14
92	Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. <i>Clinics in Liver Disease</i> , 2003 , 7, 667-81	4.6	7
91	Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. <i>Gastroenterology</i> , 2003 , 124, 642-50	13.3	283
90	Extracorporeal liver support with MARS in liver failure: has it a role in the treatment of severe alcoholic hepatitis?. <i>Journal of Hepatology</i> , 2003 , 38, 104-6	13.4	6
89	Liver transplantation in patients with HIV infection. <i>Journal of Hepatology</i> , 2003 , 39, 3-6	13.4	58
88	Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. <i>Journal of Hepatology</i> , 2003 , 39 Suppl 1, S181-9	13.4	31

87	Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. <i>Journal of Hepatology</i> , 2003 , 39, 587-94	13.4	134
86	Clinical and histological follow-up after liver transplantation (LT) for hereditary hemochromatosis (HH). <i>Journal of Hepatology</i> , 2003 , 38, 38	13.4	638
85	A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. <i>Gut</i> , 2003 , 52, 893-7	19.2	135
84	Treatment of patients with hepatic failure. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17 Suppl 3, S274-9	4	2
83	Antituberculous drugs in patients with chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17 Suppl 3, S408-12	4	9
82	Accuracy of bile duct changes for the diagnosis of chronic liver allograft rejection: reliability of the 1999 Banff schema. <i>Hepatology</i> , 2002 , 35, 117-25	11.2	26
81	I favor therapy for hepatitis C virus recurrence after transplantation. <i>Liver Transplantation</i> , 2002 , 8, S55-8	4.5	3
80	Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. <i>Gut</i> , 2002 , 50, 95-9	19.2	91
79	Prognostic value of quantitative Kaposi sarcoma--associated herpesvirus load in posttransplantation Kaposi sarcoma. <i>Journal of Infectious Diseases</i> , 2002 , 186, 110-3	7	85
78	Decision for Retransplantation of the Liver. <i>Annals of Surgery</i> , 2002 , 236, 713-721	7.8	149
77	Liver transplantation in Italy. Letter to Italian friends. <i>Digestive and Liver Disease</i> , 2002 , 34, 619-20	3.3	5
76	Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. <i>Gastroenterology</i> , 2002 , 122, 923-30	13.3	335
75	Cutaneous thrombotic microangiopathy during treatment with alpha-interferon for chronic hepatitis C. <i>Journal of Hepatology</i> , 2002 , 37, 871-2	13.4	9
74	Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients. <i>Journal of Hepatology</i> , 2002 , 36, 32	13.4	7
73	Liver transplantation for fulminant hepatic failure due to cocaine intoxication in an alcoholic hepatitis C virus-infected patient. <i>Transplantation</i> , 2002 , 73, 157-8	1.8	3
72	Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. <i>Transplantation</i> , 2002 , 73, 257-64	1.8	64
71	Decision for retransplantation of the liver: an experience- and cost-based analysis. <i>Annals of Surgery</i> , 2002 , 236, 713-21; discussion 721	7.8	28
70	Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants. <i>Blood</i> , 2001 , 98, 1332-8	2.2	32

69	Low rejection rates with tacrolimus-based dual and triple regimens following liver transplantation. <i>Clinical Transplantation</i> , 2001 , 15, 159-66	3.8	14
68	Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen. <i>Journal of Medical Virology</i> , 2001 , 65, 493-504	19.7	9
67	Successful tacrolimus therapy for a severe recurrence of type 1 autoimmune hepatitis in a liver graft recipient. <i>Liver Transplantation</i> , 2001 , 7, 556-8	4.5	44
66	Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. <i>Journal of Hepatology</i> , 2001 , 34, 943-5	13.4	20
65	Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2001 , 35, 590-7	13.4	142
64	Mortality and long term outcome of combined liver and kidney transplantations. <i>Transplantation Proceedings</i> , 2001 , 33, 1179-80	1.1	8
63	Auxiliary partial orthotopic versus standard orthotopic whole liver transplantation for acute liver failure: a reappraisal from a single center by a case-control study. <i>Annals of Surgery</i> , 2001 , 234, 723-31	7.8	77
62	Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apoptosis after liver transplantation for hepatitis C. <i>Transplantation</i> , 2000 , 70, 1390-6	1.8	29
61	Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. <i>Journal of Viral Hepatitis</i> , 2000 , 7, 87-92	3.4	41
60	Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. <i>Hepatology</i> , 2000 , 32, 1189-95	11.2	199
59	Fulminant non-A-G viral hepatitis leading to liver transplantation. <i>Archives of Internal Medicine</i> , 2000 , 160, 388-92		18
58	Hepatitis and solid organ transplantation. <i>Transplantation Proceedings</i> , 2000 , 32, 454-7	1.1	21
57	Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. <i>Journal of the American College of Surgeons</i> , 1999 , 189, 584-93	4.4	100
56	"Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. <i>Hepatology</i> , 1999 , 30, 1144-50	11.2	82
55	Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. <i>Liver Transplantation</i> , 1999 , 5, 166-74		27
54	Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. <i>Journal of Hepatology</i> , 1999 , 30, 131-41	13.4	158
53	Evaluation of efficacy of liver transplantation in alcoholic cirrhosis using matched and simulated controls: 5-year survival. Multi-centre group. <i>Journal of Hepatology</i> , 1999 , 30, 1130-7	13.4	86
52	Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1999 , 31, 584-92	13.4	27

51	Recurrence of hepatitis C virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1999 , 31 Suppl 1, 217-21	13.4	24
50	Rheumatic complications following liver transplantation. <i>Transplantation Proceedings</i> , 1999 , 31, 1717-8	1.1	12
49	European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. <i>Gastroenterology</i> , 1999 , 117, 619-25	13.3	307
48	Will transplantation of an hepatitis C-infected graft improve the outcome of liver transplantation in HCV patients?. <i>Gastroenterology</i> , 1999 , 117, 263-5	13.3	16
47	Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets. <i>Journal of Virology</i> , 1999 , 73, 9213-21	6.6	92
46	Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)- or cyclosporine-based immunosuppression. <i>Liver Transplantation</i> , 1998 , 4, 146-51		19
45	Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients. <i>Kidney International</i> , 1998 , 54, 1311-9	9.9	46
44	What should we expect from a bioartificial liver in fulminant hepatic failure?. <i>Artificial Organs</i> , 1998 , 22, 26-31	2.6	17
43	Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. <i>Transplantation Proceedings</i> , 1998 , 30, 1394-6	1.1	5
42	Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. <i>Transplantation</i> , 1998 , 65, 1328-33	1.8	52
41	Transfer of symptomatic peanut allergy to the recipient of a combined liver-and-kidney transplant. <i>New England Journal of Medicine</i> , 1997 , 337, 822-4	59.2	140
40	Experience in one center of combined kidney and liver transplantation in 22 patients: incidence of graft rejection and long-term graft outcome. <i>Transplantation Proceedings</i> , 1997 , 29, 243-4	1.1	6
39	Assessment of the results of liver transplantation and definition of criteria for the evaluation of transplant centers. <i>Transplantation Proceedings</i> , 1997 , 29, 456-8	1.1	4
38	Long-term results of combined kidney and liver transplantation at one center. <i>Transplantation Proceedings</i> , 1997 , 29, 2365-6	1.1	13
37	Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. <i>Journal of Hepatology</i> , 1997 , 26, 228-35	13.4	89
36	De novo and apparent de novo hepatitis B virus infection after liver transplantation. <i>Journal of Hepatology</i> , 1997 , 26, 517-26	13.4	132
35	Hepatitis viruses and liver transplantation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997 , 12, S335-41	4	24
34	Prolonged interferon-alpha therapy of hepatitis B virus-related decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 1997 , 4 Suppl 1, 21-6	3.4	19

33	Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. <i>Hepatology</i> , 1997 , 26, 1343-1350	11.2	83
32	Risk of liver retransplantation for viral hepatitis 1997 , 39-43		
31	Liver transplantation in Europe for patients with acute liver failure. <i>Seminars in Liver Disease</i> , 1996 , 16, 415-25	7.3	107
30	Liver transplantation in patients with acute liver failure: the European experience 1996 , 186-200		2
29	Auxiliary partial orthotopic liver transplantation for fulminant hepatitis. The Paul Brousse experience. <i>Annals of Surgery</i> , 1996 , 224, 712-24; discussion 724-6	7.8	74
28	Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. <i>Gastroenterology</i> , 1995 , 108, 1088-96	13.3	244
27	Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. <i>Journal of Hepatology</i> , 1995 , 22, 597	13.4	56
26	Sclerosing cholangitis following human orthotopic liver transplantation. <i>American Journal of Surgical Pathology</i> , 1995 , 19, 81-90	6.7	67
25	THE USE OF ABO-INCOMPATIBLE GRAFTS IN LIVER TRANSPLANTATION. <i>Transplantation</i> , 1995 , 59, 1124-1132	4.1	112
24	Combined liver and kidney transplantation in patients with chronic nephritis associated with end-stage liver disease. <i>Nephrology Dialysis Transplantation</i> , 1995 , 10 Suppl 6, 129-33	4.3	28
23	Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. <i>Annals of Surgery</i> , 1995 , 222, 109-19	7.8	229
22	Liver transplantation for hepatitis B virus infection. <i>Liver Transplantation</i> , 1995 , 1, 270-4		8
21	Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. <i>Hepatology</i> , 1995 , 21, 333-339	11.2	121
20	Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. <i>Hepatology</i> , 1995 , 21, 929-932	11.2	64
19	An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. <i>Hepatology</i> , 1995 , 22, 1084-1089	11.2	203
18	Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis 1995 , 21, 333		10
17	Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid 1995 , 21, 929		4
16	Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease. <i>Hepatology</i> , 1994 , 19, 6-12	11.2	48

15	The course of hepatitis C virus infection after liver transplantation. <i>Hepatology</i> , 1994 , 20, 1137-43	11.2	182
14	'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. <i>Journal of Hepatology</i> , 1994 , 21, 1140-3	13.4	58
13	The course of hepatitis C virus infection after liver transplantation*1. <i>Hepatology</i> , 1994 , 20, 1137-1143	11.2	201
12	Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. <i>Journal of Hepatology</i> , 1993 , 18, 119-22	13.4	46
11	Liver transplantation in cirrhosis due to hepatitis D virus infection. <i>Journal of Hepatology</i> , 1993 , 17 Suppl 3, S154-6	13.4	6
10	Liver transplantation in European patients with the hepatitis B surface antigen. <i>New England Journal of Medicine</i> , 1993 , 329, 1842-7	59.2	880
9	Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. <i>Gastroenterology</i> , 1993 , 104, 549-55	13.3	195
8	HCV type II has a more pathogenic course after liver transplantation. <i>Hepatology</i> , 1993 , 18, A59	11.2	11
7	LIVER TRANSPLANTATION FOR HEPATITIS B. <i>Gastroenterology Clinics of North America</i> , 1993 , 22, 271-284	13.4	16
6	Fipexide-induced fulminant hepatitis. Report of three cases with emergency liver transplantation. <i>Journal of Hepatology</i> , 1992 , 15, 144-6	13.4	17
5	Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model. <i>Transplantation</i> , 1990 , 49, 1155-8	1.8	145
4	Fine-needle aspiration biopsy of human liver allografts. Correlation with liver histology for the diagnosis of acute rejection. <i>Transplantation</i> , 1990 , 50, 704-7	1.8	8
3	Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients. <i>Journal of Hepatology</i> , 1990 , 11, 102-10	13.4	18
2	Liver Transplantation for Protoporphyrria. <i>Gastroenterology</i> , 1988 , 95, 816-819	13.3	63
1	Selection and Evaluation of the Recipient (Including Retransplantation)1-12		